Karyopharm Therapeutics Inc

NASDAQ:KPTIUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.

Contact Information

Headquarters

85 Wells Avenue, Second FloorNEWTON, MA, United States 02459

Phone

617-658-0600

Fax

302-655-5049

Executives

President, Chief Executive Officer, Director

Richard Paulson

Executive Vice President, Chief Commercial Officer

Sohanya Cheng

Senior Vice President - Strategy and Portfolio Management

Stuart Poulton

Executive Vice President, Chief Medical Officer

Reshma Rangwala

Senior Vice President, General Counsel, Secretary

Michael Mano